Background: Serum calcium abnormalities have been determined to be associated with the risk and outcome of stroke. The aim of the present study was to examine the associations of serum calcium with vascular recanalization, symptomatic intracranial haemorrhage and functional outcome in stroke patients after mechanical thrombectomy.

Methods: A total of 192 patients treated with mechanical thrombectomy for anterior circulation large vessel occlusion were consecutively included from August 2017 to June 2021. Serum calcium levels were measured on admission, and albumin-corrected calcium levels were calculated for subsequent analysis. Successful arterial revascularization was defined as a modified Thrombolysis in Cerebral Infarction scale score ≥ 2b. Symptomatic intracranial haemorrhage was assessed according to the European Cooperative Acute Stroke Study (ECASS) III criteria. Poor functional outcome was defined as a modified Rankin Scale score > 2 at 3 months.

Results: Patients with poor outcomes had higher albumin-corrected calcium levels than patients with good outcomes before (2.20 (2.10, 2.30) mmol/L vs. 2.13 (2.04, 2.24) mmol/L, P = 0.002), and after adjusting for other factors (AOR 95% CI, 1.812 (1.253, 2.621), P = 0.002). Patients with unsuccessful recanalization had higher albumin-corrected calcium levels than those with recanalization (2.26 (2.09, 2.46) mmol/L vs. 2.17 (2.07, 2.27) mmol/L, P = 0.029), and after adjusting for other factors (AOR 95% CI, 2.068 (1.214, 3.524)), P = 0.008). No association was found between albumin-corrected calcium and symptomatic intracranial haemorrhage.

Conclusions: Higher serum albumin-corrected calcium levels are independently associated with revascularization and poor outcome in stroke patients after mechanical thrombectomy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438214PMC
http://dx.doi.org/10.1186/s12883-022-02856-2DOI Listing

Publication Analysis

Top Keywords

albumin-corrected calcium
24
calcium levels
24
mechanical thrombectomy
12
serum calcium
12
outcome stroke
12
symptomatic intracranial
12
calcium
9
higher serum
8
serum albumin-corrected
8
associated revascularization
8

Similar Publications

Article Synopsis
  • The study investigates the relationship between primary hyperparathyroidism (PHPT) and lipid metabolism, analyzing clinical data and fat distribution in 157 PHPT patients compared to matched controls.
  • Previous research hints at a link between parathyroid hormone (PTH) levels and lipid profiles, yet this study finds no significant differences in lipid-related measurements or fat distribution between PHPT patients and controls.
  • Overall, the analysis suggests that PTH levels do not have a significant impact on lipid metabolism indicators, as various correlations remained non-significant even after accounting for factors like calcium levels and vitamin D.
View Article and Find Full Text PDF

Background: Magnesium sulfate (MgSO) is a tocolytic agent used to treat gestational hypertension and to prevent preterm labor. Neonatal hypocalcemia is a well-known side effect of maternal MgSO use. Cases of neonatal hypercalcemia after maternal MgSO have been reported.

View Article and Find Full Text PDF

Background: We found that a subset of patients with monoclonal gammopathy exhibited hypercalcemia without apparent causes or clinical manifestations In a cohort of 289 monoclonal gammopathy patients, 2.4% presented with such atypical hypercalcemia, with one notable case exhibiting normal ionized calcium levels, suggesting the presence of pseudohypercalcemia.

Objective: The aim of this study is to elucidate the factors contributing to pseudohypercalcemia in monoclonal gammopathy and to develop a novel globulin-corrected calcium formula for clinical application.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with osteoporosis and advanced chronic kidney disease (CKD) are at increased risk for low calcium levels (hypocalcemia) when starting denosumab, but it's uncertain if later doses carry the same risk.
  • An observational study analyzed data from 10,398 patients to determine how denosumab affects calcium levels with each dose, measuring changes in serum calcium and the incidence of hypocalcemia.
  • Results showed that while the first dose significantly lowered calcium levels, subsequent doses had a smaller effect, particularly in patients with severe CKD (GFR < 30 ml/min).
View Article and Find Full Text PDF

Objective: To analyze the prevalence of hyperparathyroidism in patients treated with zoledronic acid (ZA) or denosumab, its relationship with other parameters and how it affects on bone mineral density (BMD) evolution.

Methods: Retrospective observational study in patients with osteoporosis or osteopenia and high risk of fracture, who have received denosumab or ZA for at least two years. Patients diagnosed with hyperparathyroidism or glomerular filtration rate <30ml/min at baseline visit were excluded from the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!